Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Neurocytometry: A New Method to Assess Ocular Pain-Associated Markers in Trigeminal Ganglion
Author Affiliations & Notes
  • Amirreza Naderi
    Yale School of Medicine, New Haven, Connecticut, United States
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Pier Luigi Surico
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Yeganeh Farsi
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Yihe Chen
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Reza Dana
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Amirreza Naderi None; Pier Luigi Surico None; Yeganeh Farsi None; Yihe Chen None; Reza Dana None
  • Footnotes
    Support  DOD Grant W81XWH-21-1-0839
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2657. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amirreza Naderi, Pier Luigi Surico, Yeganeh Farsi, Yihe Chen, Reza Dana; Neurocytometry: A New Method to Assess Ocular Pain-Associated Markers in Trigeminal Ganglion. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2657.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ocular pain is a common symptom of dry eye disease (DED). However, studying ocular pain at a molecular level has been challenging due to the limited number of cornea-innervating neurons in the trigeminal ganglion (TG), the laborious process to prepare the tissue for immunohistochemistry and challenges in quantifying the results. Here, we introduce a new approach to specifically quantify corneal-innervating TG neurons through retrograde labeling and assess their Fos expression, the molecular marker of neuronal activation, with a flow cytometric approach.

Methods : 6-week-old C57BL/6 female mice were housed under desiccating stress in a controlled environment chamber for 14 days to induce DED. The right eye of the DED animals and healthy control (N= 6 animals/ group) was injected intrastromally with Alexa Fluor™ 647 Conjugated-recombinant Cholera Toxin Subunit B (Ctb), 4 days prior to sacrifice. The ipsilateral trigeminal ganglion was collected and enzymatically digested using papain to prepare single cell suspension, which was subsequently fixed, permeabilized and stained with antibodies against NeuN (neuronal nuclear antigen) and Fos. The cell suspensions were analyzed using BigFoot Spectral Cell Sorter. All data were compared via student T-test.

Results : There were no significant differences among the numbers of retrograde labeled neurons (NeuN+ Ctb+) between DED animals and healthy controls (286 ± 38 vs. 366 ± 80). There was a significantly higher percentage of Fos-positive retrograde labeled neurons (NeuN+ Ctb+ Fos+) in DED subjects when compared with healthy controls (98.6 ± 0.6% vs. 88.7 ± 1.4% ; P<0.05). The mean fluorescence intensity of Fos protein among the traced Fos-positive population was nearly doubled in DED group compared to the control group (6706.5 ± 297.6 vs. 3620.7 ± 211.1 ; P<0.01). Furthermore, the frequency of untraced Fos-positive neurons (NeuN+ Ctb- Fos+) were similar in the two groups (40.0 ± 4.5% vs. 41.8 ± 3.1%). Accordingly, the mean fluorescence intensity of Fos protein among the untraced Fos-positive population had no significant difference either (1007.8 ± 22.2 vs. 1043.4 ± 27.8).

Conclusions : Flow cytometric analysis of specific cornea-innervating neurons in trigeminal ganglion is a relatively efficient and more accurate method to assess expression of proteins associated with ocular pain.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×